Deelnemende ziekenhuizen

In voorbereiding

  • Radboudumc (S. Langemeijer)

Officiƫle titel

An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)

Studiedocumenten

Klik HIER voor de afgeschermde studiedocumenten (alleen toegankelijk via netwerk Radboudumc).